相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence
Eugen Dhimolea et al.
CANCER CELL (2021)
Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy
Sumaiyah K. Rehman et al.
CELL (2021)
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
Kartik Sehgal et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
Cihangir Duy et al.
CANCER DISCOVERY (2021)
Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop
Lucine Fahy et al.
BLOOD ADVANCES (2021)
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Rong Du et al.
BMC CANCER (2021)
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Tom van den Ende et al.
CLINICAL CANCER RESEARCH (2021)
mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation
Yilei Zhang et al.
NATURE COMMUNICATIONS (2021)
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
Giulia De Conti et al.
CANCERS (2021)
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Elio Adib et al.
CLINICAL CANCER RESEARCH (2021)
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Ruchi Kumari et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
The Cancer SENESCopedia: A delineation of cancer cell senescence
Fleur Jochems et al.
CELL REPORTS (2021)
Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
Sarah E. Taylor et al.
GYNECOLOGIC ONCOLOGY (2020)
Therapy-Induced Senescence: An Old Friend Becomes the Enemy
Tareq Saleh et al.
CANCERS (2020)
The senescence-associated secretome as an indicator of age and medical risk
Marissa J. Schafer et al.
JCI INSIGHT (2020)
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia
Koichi Oshima et al.
NATURE CANCER (2020)
Exceptional response to neoadjuvant capecitabine and temozolomide in TSC2-mutant pancreatic neuroendocrine tumor
Robin Park et al.
CURRENT PROBLEMS IN CANCER: CASE REPORTS (2020)
Non-genetic mechanisms of therapeutic resistance in cancer
Jean-Christophe Marine et al.
NATURE REVIEWS CANCER (2020)
Tumor Cell Escape from Therapy-Induced Senescence as a Model of Disease Recurrence after Dormancy
Tareq Saleh et al.
CANCER RESEARCH (2019)
Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma
Colleen T. Harrington et al.
LEUKEMIA (2019)
Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
Vadim S. Koshkin et al.
INVESTIGATIONAL NEW DRUGS (2019)
Successful treatment of a TSC2-mutant glioblastoma with everolimus
Andrew H. Zureick et al.
BMJ CASE REPORTS (2019)
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
Siker Kimbung et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells
Robert J. Ihry et al.
NATURE MEDICINE (2018)
CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response
Emma Haapaniemi et al.
NATURE MEDICINE (2018)
An enhanced CRISPR repressor for targeted mammalian gene regulation
Nan Cher Yeo et al.
NATURE METHODS (2018)
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
In Hae Park et al.
JOURNAL OF CANCER (2018)
Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery
Hui-Ju Hsieh et al.
NATURE COMMUNICATIONS (2018)
mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL
Thanh-Trang T. Vo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Differential analysis of RNA-seq incorporating quantification uncertainty
Harold Pimentel et al.
NATURE METHODS (2017)
Twenty-five years of mTOR: Uncovering the link from nutrients to growth
David M. Sabatini
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and β-catenin
Kyu Sang Lee et al.
BMC CANCER (2016)
Inhibition of mTOR induces a paused pluripotent state
Aydan Bulut-Karslioglu et al.
NATURE (2016)
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
John G. Doench et al.
NATURE BIOTECHNOLOGY (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Maxim V. Kuleshov et al.
NUCLEIC ACIDS RESEARCH (2016)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
Senescence-associated inflammatory responses: aging and cancer perspectives
Audrey Lasry et al.
TRENDS IN IMMUNOLOGY (2015)
Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations
M. Moschetta et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Wei Li et al.
GENOME BIOLOGY (2014)
Genomic impact of transient low-dose decitabine treatment on primary AML cells
Jeffery M. Klco et al.
BLOOD (2013)
Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: Biological considerations about a clinical case
B. Duchemain et al.
CANCER RADIOTHERAPIE (2013)
TCPA: a resource for cancer functional proteomics data
Jun Li et al.
NATURE METHODS (2013)
Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide
D. Biasoli et al.
CELL DEATH & DISEASE (2013)
p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer
James G. Jackson et al.
CANCER CELL (2012)
RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer
Agnieszka K. Witkiewicz et al.
CLINICAL CANCER RESEARCH (2012)
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Meredith A. Collins et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
Meredith A. Collins et al.
PLOS ONE (2012)
Defective Regulation of Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo
Joon-Ho Sheen et al.
CANCER CELL (2011)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence
Agustin Chicas et al.
CANCER CELL (2010)
New specific molecular targets for radio-chemotherapy of rectal cancer
Kristin Snipstad et al.
MOLECULAR ONCOLOGY (2010)
Inflammatory networks during cellular senescence: causes and consequences
Adam Freund et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Protocols to detect senescence-associated beta-galactosidase (SA-beta gal) activity, a biomarker of senescent cells in culture and in vivo
Florence Debacq-Chainiaux et al.
NATURE PROTOCOLS (2009)
Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells
Damian J. Junk et al.
NEOPLASIA (2008)
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
Chi-Hwa Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Retinoblastoma deficiency increases chemosensitivity in lung cancer
William A. Zagorski et al.
CANCER RESEARCH (2007)
Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16INK4a
I Guney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Crm1 is a mitotic effector of Ran-GTP in somatic cells
A Arnaoutov et al.
NATURE CELL BIOLOGY (2005)
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
P Bertheau et al.
LANCET (2002)
Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres
J Munro et al.
ONCOGENE (2001)
分享论文
